Long noncoding RNA MIR22HG is down-regulated in prostate cancer

Hao Shen; Xiao-Dong Weng; Du Yang; Lei Wang; Xiu-Heng Liu; Hao Shen; Xiao-Dong Weng; Du Yang; Lei Wang; Xiu-Heng Liu

doi:10.3934/mbe.2020093

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 2: 1776-1786. doi: 10.3934/mbe.2020093

Previous Article Next Article

Research article Special Issues

Long noncoding RNA MIR22HG is down-regulated in prostate cancer

Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received: 19 May 2019 Accepted: 12 December 2019 Published: 17 December 2019

Prostate cancer (PCa) is one of the most common cancer in males. Previous studies indicated that MIR22HG was a tumor suppressor in various cancers. However, the expression pattern and functional roles of MIR22HG in PCa remained to be further investigated. In this study, we for the first time showed MIR22HG was down-regulated in PCa. Furthermore, we observed the lower expression levels of MIR22HG were significantly related to higher Gleason score and T stage. Of note, we found that higher MIR22HG expression was associated with better disease-free survival and overall survival time in PCa. Moreover, we constructed a MIR22HG mediated co-expression network. Bioinformatics analysis showed MIR22HG was associated with regulating inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, and TNF signaling pathway. These results showed that MIR22HG could serve as a novel biomarker for prostate cancer.
- long noncoding RNA,
- MIR22HG,
- protein-protein interaction,
- biomarker,
- bioinformatics analysis
Citation: Hao Shen, Xiao-Dong Weng, Du Yang, Lei Wang, Xiu-Heng Liu. Long noncoding RNA MIR22HG is down-regulated in prostate cancer[J]. Mathematical Biosciences and Engineering, 2020, 17(2): 1776-1786. doi: 10.3934/mbe.2020093

Related Papers:

Abstract

Prostate cancer (PCa) is one of the most common cancer in males. Previous studies indicated that MIR22HG was a tumor suppressor in various cancers. However, the expression pattern and functional roles of MIR22HG in PCa remained to be further investigated. In this study, we for the first time showed MIR22HG was down-regulated in PCa. Furthermore, we observed the lower expression levels of MIR22HG were significantly related to higher Gleason score and T stage. Of note, we found that higher MIR22HG expression was associated with better disease-free survival and overall survival time in PCa. Moreover, we constructed a MIR22HG mediated co-expression network. Bioinformatics analysis showed MIR22HG was associated with regulating inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, and TNF signaling pathway. These results showed that MIR22HG could serve as a novel biomarker for prostate cancer.

References

[1]	M. R. Pickard, M. Mourtada-Maarabouni, G. T. Williams, Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines, Biochim. Biophys. Acta Mol. Basis Dis., 1832 (2013), 1613-1623.
[2]	S. Cao, W. Liu, F. Li, W. Zhao, C. Qin, Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer, Int. J. Clin. Exp. Pathol., 7 (2014), 6776-6783.
[3]	X. H. Liu, M. Sun, F. Q. Nie, Y. B. Ge, E. B. Zhang, D. D. Yin, et al., Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer, Mol. Cancer, 13 (2014), 92.
[4]	X. H. Liu, Z. L. Liu, M. Sun, J. Liu, Z. X. Wang, W. De, The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer, BMC Cancer, 13 (2013), 464.
[5]	D. Chakravarty, A. Sboner, S. S. Nair, E. Giannopoulou, R. Li, S. Hennig, et al., The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer, Nat. Commun., 5 (2014), 5383.
[6]	C. Sun, S. Li, F. Zhang, Y. Xi, L. Wang, Y. Bi, et al., Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway, Oncotarget, 7 (2016), 51784-51814.
[7]	J. Fang, C. C. Sun, C. Gong, Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression, Biochem. Biophys. Res. Commun., 478 (2016), 811-817.
[8]	N. M. White, S. G. Zhao, J. Zhang, E. B. Rozycki, H. X. Dang, S. D. Mcfadden, et al., Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer, Eur. Urol., 71 (2017), 257-266.
[9]	Y. Zhang, S. Pitchiaya, M. Cieslik, Y. S. Niknafs, J. C. Y. Tien, Y. Hosono, et al., Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression, Nat. Genet., 50 (2018), 814-824.
[10]	J. Qin, H. Ning, Y. Zhou, Y. Hu, L. Yang, R. Huang, LncRNA MIR31HG overexpression serves as poor prognostic biomarker and promotes cells proliferation in lung adenocarcinoma, Biomed. Pharmacother., 99 (2018), 363-368.
[11]	J. Li, Q. M. Wu, X. Q. Wang, C. Q. Zhang, Long Noncoding RNA miR210HG Sponges miR-503 to Facilitate Osteosarcoma Cell Invasion and Metastasis, DNA Cell Biol., 36 (2017), 1117-1125.
[12]	Z. Cui, X. An, J. Li, Q. Liu, W. Liu, LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation, Biomed. Pharmacother., 104 (2018), 223-228.
[13]	D. Y. Zhang, X. J. Zou, C. H. Cao, T. Zhang, L. Lei, X. L. Qi, et al., Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma, Theranostics, 8 (2018), 3751-3765.
[14]	U. R. Chandran, C. Ma, R. Dhir, M. Bisceglia, M. Lyons-Weiler, W. Liang, et al., Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process, BMC Cancer, 7 (2007), 64.
[15]	Y. P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, et al., Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy, J. Clin. Oncol., 22 (2004), 2790-2799.
[16]	M. S. Arredouani, B. Lu, M. Bhasin, M. Eljanne, W. Yue, J. M. Mosquera, et al., Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer, Clin. Cancer Res., 15 (2009), 5794-5802.
[17]	H. Satake, K. Tamura, M. Furihata, T. Anchi, H. Sakoda, C. Kawada, et al., The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer, Oncol. Rep., 23 (2010), 11-16.
[18]	J. R. Prensner, W. Chen, M. K. Iyer, Q. Cao, T. Ma, S. Han, et al., PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer, Cancer Res., 74 (2014), 1651-1660.
[19]	J. H. Li, S. Liu, H. Zhou, L. H. Qu, J. H. Yang, starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data, Nucleic Acids Res., 42 (2014), D92-D97.
[20]	J. H. Yang, J. H. Li, P. Shao, H. Zhou, Y. Q. Chen, L. H. Qu, starBase: A database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data, Nucleic Acids Res., 39 (2011), D202-D209.
[21]	X. Filella, E. Fernandez-Galan, R. F. Bonifacio, L. Foj, Emerging biomarkers in the diagnosis of prostate cancer, Pharmgenomics Pers. Med., 11 (2018), 83-94.
[22]	B. Yang, X. Tang, Z. Wang, D. Sun, X. Wei, Y. Ding, TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a, Biosci. Rep., 38 (2018).
[23]	A. Matjasic, M. Tajnik, E. Bostjancic, M. Popovic, B. Matos, D. Glavac, Identifying novel glioma-associated noncoding RNAs by their expression profiles, Int. J. Genomics, 2017 (2017), 2312318.
[24]	P. Gu, X. Chen, R. Xie, J. Han, W. Xie, B. Wang, et al., lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5, Mol. Ther., 25 (2017), 1959-1973.
[25]	Y. Lu, X. Zhao, Q. Liu, C. Li, R. Graves-Deal, Z. Cao, et al., lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling, Nat. Med., 23 (2017), 1331-1341.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)